<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00137813</url>
  </required_header>
  <id_info>
    <org_study_id>04-179</org_study_id>
    <nct_id>NCT00137813</nct_id>
  </id_info>
  <brief_title>Avastin and Taxotere for Esophagogastric Cancer</brief_title>
  <official_title>Phase II Study of Bevacizumab and Docetaxel (AvaTax) in Metastatic Esophagogastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine what effects (good and bad) bevacizumab (Avastin)&#xD;
      and docetaxel (Taxotere), used in combination, have on metastatic gastric and esophageal&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bevacizumab will be administered intravenously in an outpatient clinic once a week, every&#xD;
      other week. Docetaxel will also be administered intravenously in the outpatient clinic once a&#xD;
      week for three out of four weeks. Blood tests and vital signs will be performed weekly.&#xD;
&#xD;
      After the first eight weeks of therapy a CT scan will be performed to determine and assess&#xD;
      the progress of the disease. If therapy is continued, radiological procedures will be&#xD;
      performed at week 16 and every 8 weeks thereafter.&#xD;
&#xD;
      Treatment will be given for a minimum of 8 weeks, as long as the patient does not experience&#xD;
      unacceptable side effects. Chemotherapy will continue for a year and a half as long as the&#xD;
      cancer is responding and there are no unacceptable side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the overall response and safety of the combination docetaxel and bevacizumab in patients with esophageal or gastric cancer</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the duration of response, progression-free and overall survival of patients with esophageal or gastric cancer treated with docetaxel and bevacizumab</measure>
  </secondary_outcome>
  <enrollment type="Actual">42</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Given intravenously once a week for 3 out of four weeks for a minimum of 8 weeks and maximum of a year and a half</description>
    <other_name>AvaTax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Given intravenously once a week for every other week for a minimum of 8 weeks and a maximum of a year and a half</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed, unresectable or metastatic stage IV esophageal or gastric&#xD;
             carcinoma&#xD;
&#xD;
          -  Measurable disease greater than or equal to 1cm by spiral computed tomography (CT)&#xD;
             scan or greater than or equal to 2cm by other radiographic technique&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  One prior chemotherapy for metastatic disease permitted&#xD;
&#xD;
          -  White blood cell count greater than or equal to 3,000/mm&#xD;
&#xD;
          -  Absolute neutrophil count greater than or equal to 1,500/mm3&#xD;
&#xD;
          -  Platelet count greater than or equal to 100,000/mm3&#xD;
&#xD;
          -  Hemoglobin greater than or equal to 8.0g/dl&#xD;
&#xD;
          -  Creatinine less than 2.0mg/dL&#xD;
&#xD;
          -  Total bilirubin less than 1.9mg/dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  History or evidence of central nervous system (CNS) disease&#xD;
&#xD;
          -  Other active malignancies other than non-melanoma skin cancer or in-situ cervical&#xD;
             cancer&#xD;
&#xD;
          -  History of severe hypersensitivity to docetaxel, bevacizumab or drugs formulated with&#xD;
             polysorbate 80.&#xD;
&#xD;
          -  Current, recent or planned treatment with standard chemotherapy, radiation therapy or&#xD;
             another experimental therapy.&#xD;
&#xD;
          -  History of other disease or metabolic dysfunction.&#xD;
&#xD;
          -  Serious, non-healing wound, ulcer, or bone fracture.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Enzinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>August 29, 2005</study_first_submitted>
  <study_first_submitted_qc>August 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2005</study_first_posted>
  <last_update_submitted>October 31, 2018</last_update_submitted>
  <last_update_submitted_qc>October 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Peter C. Enzinger, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Bevacizumab</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>AvaTax</keyword>
  <keyword>Metastatic Esophagogastric Cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

